Stay updated with breaking news from Nick Leschly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell...
Regeneron Pharmaceuticals is paying $5 million up front for 2seventy bio’s cancer drug pipeline. 2seventy will now focus on a cell therapy commercialized with partner Bristol Myers Squibb while Regeneron adds assets for its newly formed cell therapy division.
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price […]
(Reuters) -Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio, urging a board refresh a...